Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1106-1112. doi: 10.1051/medsci/2019223. Epub 2020 Jan 6.

[New formats for improving brain drug delivery of antibodies: the blood-brain barrier case].

[Article in French; Abstract available in French from the publisher]

Author information

Institut Pasteur, Plateforme d'ingénierie des anticorps, Paris, France.
Sanofi, Département des Maladies Rares et Neurologiques, Groupe Barrières Cérébrales, Paris, France.
Université Paris Descartes, Faculté de Pharmacie de Paris et Inserm UMRS-1144, Barrière hémato-encéphalique: Physiopathologie et Thérapie, Paris, France.


in English, French

Many neurodegenerative or tumor brain pathologies should be able to benefit from the impressive medicinal advances that represent therapeutic antibodies. Unfortunately, many failures have been observed with antibodies whose targets are in the brain parenchyma due to their very low brain distribution. The blood-brain barrier (BBB) that exhibits extremely selective and restrictive properties is responsible for the low brain penetration of high-molecular mass molecules including therapeutic antibodies. The objective of this article is to present the properties of the BBB and the latest advances in the engineering of new antibody formats to possibly improve their brain distribution.


Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center